Biochips: Bright Future in Clinical Dx?
|M. Kohl1, S. Koch2, M. Keller3 and H.P. Deigner1,2*|
|1Furtwangen University, 78054 Villingen-Schwenningen, Germany|
|2Fraunhofer Institute IZI, Leipzig/EXIM Rostock, 18057 Rostock, Germany|
|3Clinics Essen, Centre for Pediatrics, 45147 Essen|
|Corresponding Author :||Dr. Hans-Peter Deigner
Fraunhofer Institut IZI, Leipzig/ EXIM Rostock
18057 Rostock and Furtwangen University
78054 Villingen- Schwenningen, Germany
|Received September 10, 2010; Accepted September 10, 2011; Published October 29, 2011|
|Citation: Kohl M, Koch S, Keller M, Deigner HP (2011) Biochips: Bright Future in Clinical Dx? J Biochip Tissue chip S1:003. doi: 10.4172/2153-0777.S1-e003|
|Copyright: © 2011 Kohl M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
Biochips play an established important role in research on disease biology and systems biology while an increasing number of clinical applications is emerging. What about the future of biochips in medical routine? The term biochip as used by us in this editorial is confined to chips in DNA/RNA analysis, just for sake of brevity, not implying any judgement. We hypothesize that the future will bring a routine use of biochips in diagnostics and provide arguments to support our view. We comment on technological and data analysis aspects, also with regard to 3rd generation sequencing, and point out remaining challenges. We foresee an increasing application of biochips in the clinic and beyond, in the hand of practitioners. What are the reasons to justify the optimism about biochips potential to accelerate not only the understanding of the biological basis of diseases but to develop into an integral part of medicinal diagnostics.